AMARIN CORP PLC\UK Cash and Restricted Cash
AMARIN CORP PLC\UK (AMRN) had Cash and Restricted Cash of $129.65 million as of 2018-03-31, per its 10-Q filed 2018-05-02.
Discontinued › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2018-05-02
- 2018-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $129.65M.
- 2017-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $74.24M.
- 2017-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $96.68M.
- 2016-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $98.85M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2018-03-31 | $129.65M 10-Q · filed 2018-05-02 |
| 2017-12-31 | $74.24M 10-Q · filed 2018-05-02 |
| 2017-03-31 | $96.68M 10-Q · filed 2018-05-02 |
| 2016-12-31 | $98.85M 10-Q · filed 2018-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |